Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-claudin-1 monoclonal antibody ALE.C04

A humanized monoclonal antibody directed against the tumor-associated antigen (TAA) claudin-1 (CLDN1; CLDN-1), with potential immunostimulating and antineoplastic activities. Upon administration, anti-CLDN1 monoclonal antibody ALE.C04 targets and binds to a specific extracellular loop epitope that is exposed in non-junctional (NJ) CLDN1 expressed on certain tumor cells. This prevents CLDN1-mediated signaling, which disrupts the stiff extracellular matrix (ECM) in tumors and, by disturbing the physical barrier, enhances the infiltration of immune cells, such as natural killer cells (NKs) and T cells. This abrogates immunosuppression in the tumor microenvironment (TME) and leads to NK- and T-cell-mediated tumor cell killing. In addition, ALE.C04 can directly kill CLDN1-expressing tumor cells via antibody-dependent cell mediated cytotoxicity (ADCC). CLDN1, which is normally confined within the tight junctions in epithelial tissues, is overexpressed on a variety of tumor cells in a non-junctional form. CLDN1 overexpression on tumor cells correlates with ECM remodeling and T-cell exclusion, and is associated with reduced efficacy of checkpoint inhibitors (CPIs).
Synonym:anti-claudin 1 monoclonal antibody ALE.C04
anti-CLDN1 monoclonal antibody ALE.C04
Code name:ALE C04
ALE-C04
ALE.C04
ALEC04
Search NCI's Drug Dictionary